Investors

Home / Investors / Press Releases

Press Releases

8Dec

CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors

7Dec

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis

6Dec

CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar

28Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

10Nov

CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City

10Nov

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis

9Nov

CymaBay Reports Third Quarter 2016 Financial Results

9Nov

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)

2Nov

CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

RSS
Show All

Contact Info

  • 7575 Gateway Blvd., Suite 110
    Newark, CA 94560
  • +1 (510) 293-8800
  • +1 (510) 293-9090

Quick Links

Pipeline